J Korean Med Sci.  2005 Oct;20(5):883-885. 10.3346/jkms.2005.20.5.883.

Successful Treatment of Refractory Thrombocytopenia with Mycophenolate Mofetil in a Patient with Systemic Lupus Erythematosus

• Chang HK

• KMID: 1781776
• DOI: http://doi.org/10.3346/jkms.2005.20.5.883

Abstract

While mild thrombocytopenia in systemic lupus erythematosus (SLE) is frequently seen in the context of active disease, severe thrombocytopenia causing significant bleeding is not that common. Corticosteroids are considered the first line therapy for severe thrombocytopenia in SLE. Second-line therapeutic agents or splenectomy have been reported to be effective for patients who fail to respond to steroids or those who require moderate doses of steroids to maintain the platelet counts. Recent randomized controlled studies have shown that mycophenolate mofetil (MMF) is an efficacious and safe therapeutic agent in patients with proliferative forms of lupus nephritis. However, little information has been available regarding the role of MMF in the treatment of immune thrombocytopenia complicated with SLE. Hereby I describe a patient with SLE in whom thrombocytopenia was refractory to corticosteroids, intermittent intravenous cyclophosphamide, azathioprine, cyclosporine, intravenous gamma globulin, danazol, and splenectomy, and whose platelet counts eventually normalized during therapy with MMF. In this patient, thrombocytopenia is initially thought to be associated with active SLE involving major organ. However, after immunosuppressive agents were given, the refractory nature of thrombocytopenia seems to be an isolated phenomenon, independently of SLE activity.

Keyword

Lupus Erythematosus, Systemic; Thrombocytopenia; mycophenolate mofetiI

MeSH Terms

Adrenal Cortex Hormones/therapeutic use
Adult
Female
Humans
Immunosuppressive Agents/therapeutic use
Lupus Erythematosus, Systemic/*complications/*drug therapy
Mycophenolic Acid/*analogs and derivatives/therapeutic use
Penicillin G, Benzathine/therapeutic use
Thrombocytopenia/*drug therapy/*etiology
Treatment Failure
Treatment Outcome

Reference

1. Quismorio FP Jr. Wallace DJ, Hahn BH, editors. Hematologic and lymphoid abnormalities in systemic lupus erythematosus. Dubois' lupus erythematosus. 2002. Philadelphia: Lippincott Williams & Wilkins;793–819.

2. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000. 47:85–118.

3. Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus. 2001. 10:203–208.

4. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int. 1997. 51:1583–1589.

5. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN. Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000. 343:1156–1162.

6. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004. 350:971–980.

7. Miller MH, Urowitz MB, Gladman DD. The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum. 1983. 26:1181–1186.

8. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002. 29:75–83.

9. Alarcon-Segovia D. Splenectomy has a limited role in the management of lupus with thrombocytopenia. J Rheumatol. 2002. 29:1–2.

10. Rivero SJ, Alger M, Alarcon-Segovia D. Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal. Arch Intern Med. 1979. 139:773–776.

11. Homan WP, Dineen P. The role of splenectomy in the treatment of thrombocytopenic purpura due to systemic lupus erythematosus. Ann Surg. 1978. 187:52–56.

12. Jayne D. Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens. 1999. 8:563–567.

13. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus. 2003. 12:630–632.

14. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002. 117:712–715.

15. Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, Ji X, Wang X, Zhang M. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003. 70:353–357.